Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET
Company Participants
Andrea Flynn - Vice President, Head, Investor Relations
Bruce Cozadd - Chairperson and Chief Executive Officer
Renee Gala - President and Chief Operating Officer
Rob Iannone - Executive Vice President, Global Head of Research and Development
Conference Call Participants
Jessica Fye - JPMorgan Chase & Co.
Marc Goodman - Leerink Partners
Jason Gerberry - Bank of America Merrill Lynch
Ami Fadia - Needham & Company
Ashish Verma - UBS
Joseph Thome - TB Cowen
Gregory Renza - RBC Capital Markets
Annabel Samimy - Stifel
David Amsellem - Piper Sandler & Co.
June Lee - Truist Securities
Gary Nachman - Raymond James & Associates
Michael Riad - Morgan Stanley
Joel Beatty - Baird
Operator
Good afternoon, ladies and gentlemen. My name is Abby and I'll be your conference operator today. At this time, I would like to welcome everyone to the Jazz Pharmaceuticals Fourth Quarter 2023 Earnings Conference Call. Today’s conference is being recorded and all lines have been placed on mute to prevent any background noise. [Operator Instructions]. Thank you.
And I’ll now turn the conference over to Andrea Flynn, Head of Investor Relations. Ms. Flynn, you may begin.
Andrea Flynn
Thank you, operator, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported its fourth quarter and fully year 2023 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also refer to the press release we issued earlier today, which is also posted to our website.
On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renee Gala, President and Chief Operating Officer; and Rob Iannone, Executive Vice President, Global Head of R&D;
On Slide 2, I'd like to remind you that today's webcast includes forward-looking statements, such as those related to our future financial and operating results, growth potential and anticipated development and commercialization milestones and goals, which involve risks and uncertainties that could cause actual events, performance and results to differ materially from those contained in these forward-looking statements.
We encourage you to review the statements contained in today's press release, in our slide deck and the risks and uncertainties described in our SEC filings which identify certain factors that may cause the company's actual events, performance and results to differ materially from those contained in the forward-looking statements made on today's webcast. We undertake no duty or obligation to update our forward-looking statements.